Cancer Vaccines Market

The global cancer vaccines market is anticipated to reach USD 20.47 billion by 2032 from USD 10.61 billion in 2024, with a significant CAGR of 8.6%. Increased investments in research and development of neoantigen cancer vaccines and technological advancements are some of the factors driving the market's growth. Furthermore, the shift towards preventive healthcare and the rising incidence of cancer are increasing demand for cancer vaccines, further boosting the market's growth in coming years.

The market for cancer vaccines market is consolidated, with key players strategizing to capture the majority of the market. Prominent players in the cancer vaccines market are Merck & Co., Inc. (US), GSK plc (UK), Dendreon Pharmaceuticals LLC (US), JW CreaGene (Korea), Serum Institute of India Pvt. Ltd. (India), Verity Pharmaceuticals, Inc. (Canada), Wantai BioPharm (China), Vaccinogen (US) and Shanghai Zerun Biotechnology Co., Ltd. (China) among others. The market players have adopted various strategies such as development of advanced products, partnerships, contracts, expansions, and acquisitions to strengthen their position in the cancer vaccines market.

To know about the assumptions considered for the study download the pdf brochure

Merck & Co., Inc. is one of the top players in the cancer vaccines market through its innovative strategies, in-depth clinical research, and powerful collaborations. The strategic partnership between Merck and Moderna in co-developing mRNA-based personalized cancer vaccines, like mRNA-4157 (V940), showcase its leadership role in using next-generation technologies. Recently initiated Phase 3 trial for mRNA-4157 in combination with KEYTRUDA shows its commitment to developing innovative therapies for solid tumors and adds to its stronghold in the market. Merck's significant investments in R&D for novel cancer vaccines constitute serious commitment to diversify its oncology pipeline beyond currently available therapies. These investments are especially important in the context of exploring treatment avenues for difficult cancers, including advanced solid tumors. This focus on precision medicine and cutting-edge vaccine technology places Merck at the forefront of the swiftly developing market.

GSK Plc is one of the most advanced companies of the generation in the oncology vaccine market, and it has gained notable repute due to its innovative approaches toward immuno-oncology, thus giving great importance to precision medicine. Vaccines like Cervarix have become part of HPV-related cervical cancers prevention. GSK, meanwhile, pursues its oncology pipeline and has targeted drug development on the unmet needs by tapping into progressive research in human genetics and the immune system. GSK's latest directive from the top is to hasten tumor-targeting therapies and immuno-oncology solutions to solidify its driving position on advancing the preventive and therapeutic options for combating cancers.

Related Reports:

Cancer Vaccines Market by Type (Preventive, Therapeutic [Neoantigen]), Technology (Cell-based Vaccine, Recombinant), Indication (Cervical, Prostate), ROA (Intramuscular, Intravenous), End User (Hospitals, Speciality Clinics) - Global Forecast to 2032

Contact:
Mr. Rohan Salgarkar
MarketsandMarkets™ INC.
1615 South Congress Ave.
Suite 103, Delray Beach, FL 33445
USA : 1-888-600-6441
[email protected]